Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With GeneKor to Include Turkey and Romania
November 20 2013 - 8:30AM
Marketwired
Rosetta Genomics Expands microRNA Cancer Testing Services Agreement
With GeneKor to Include Turkey and Romania
PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Nov 20, 2013)
- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces the
expansion of its distribution agreement with GeneKor Medical S.A
for the exclusive sales and marketing of the Company's suite of
microRNA-based cancer testing services in Romania and non-exclusive
distribution in Turkey, in addition to the original agreement
covering Greece. GeneKor is a leading molecular diagnostic
service provider based in Greece.
"We are delighted to expand our relationship with GeneKor, a
leading molecular diagnostics company with experience in
distributing high-complexity oncology tests. We look forward
to building upon our established relationship to leverage the need
for better cancer diagnostics with Rosetta's powerful
microRNA-based product portfolio," stated Kenneth A. Berlin,
President and Chief Executive Officer of Rosetta
Genomics. "Developments in targeted cancer therapies are
driving the need for more accurate classification of tumor types to
guide treatment decisions. Our microRNA technologies, with
their high reproducibility, robustness and accuracy, are well
suited to provide valuable clinical information to predict and
diagnose cancer, and therefore to help optimize treatment."
E. Robert Wassman, MD, FAAP, FACMG, Rosetta Genomics' Chief
Medical Officer, said: "This extension to our agreement with
Genekor will enhance patient access to our microRNA-based testing
services in Turkey and Romania, and will potentially result in more
personalized treatment approaches for many patients. In addition,
this new agreement underscores our commitment to expand
personalized medicine across the globe, and to help improve patient
outcomes."
About Rosetta Cancer Testing Services Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta
Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test™ accurately
identifies the four main subtypes of lung cancer using small
amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately
classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta's assays are designed to provide objective
diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S.
alone, Rosetta Genomics estimates that 200,000 patients a year may
benefit from the Rosetta Cancer Origin Test™, 60,000 from the
Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer
Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The
Company's assays are offered directly by Rosetta Genomics in the
U.S., and through distributors around the world. For more
information, please visit www.rosettagenomics.com. Parties
interested in ordering the test can contact Rosetta Genomics at
(215) 382-9000 ext. 309.
About GeneKor GeneKor Medical S.A. was founded in 2007 and
operates molecular biology laboratories with state-of-the-art
equipment suitable to provide the highest quality services. GeneKor
provides a diversification of services focused on improving patient
care utilizing the latest technologies of prognostic, predictive
and personalized medicine. As of June 2012, the specialized
laboratory of GeneKor has been accredited by ISO 15189:2007
for Clinical Laboratories by the Hellenic Accreditation System S.A.
(Ε.ΣΥ.Δ.), while it has also been certified by International
quality Standards Organizations (ISO 9001:2008), from independent
international certification bodies (TUV Nord). GeneKor services are
assured through External Quality Assurance by the European
Molecular Genetics Quality Network (EMQN), the National External
Quality Assessment Service (UK NEQAS) and the College of American
Pathologist (CAP). GeneKor. is staffed by board-certified
internationally recognized and published scientists and doctors who
are able to provide analyses and recommendations to physicians and
their patients. As such, GeneKor. is in position to carry out all
existing molecular biology assays. GeneKor offers treating
physicians various tools to individualize patient treatment.
GeneKor is devoted to offering the highest-quality services
by constantly monitoring scientific developments in the health
sector, updating its laboratory equipment and maximizing its levels
of accuracy and reliability. GeneKor is also operating in Romania
and Turkey and actively establishing its international presence
with an ultimate goal of extending its collaborations in more
countries. GeneKor's strategic goal is the constant incorporation
of new technology platforms and assays in order to consistently
provide the most up-to-date, reliable and cutting-edge tools to the
treating physicians.
About Rosetta Genomics Rosetta develops and commercializes a
full range of microRNA-based molecular diagnostics. Founded in
2000, Rosetta's integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human
microRNAs. Building on its strong patent position and proprietary
platform technologies, Rosetta is working on the application of
these technologies in the development and commercialization of a
full range of microRNA-based diagnostic tools. Rosetta's cancer
testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost
& Sullivan recognized Rosetta Genomics with the 2012 North
American Next Generation Diagnostics Entrepreneurial Company of the
Year Award.
Forward-Looking Statement Disclaimer Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test™, Rosetta's development or commercialization of molecular
diagnostics, the market acceptance of Rosetta's cancer testing
services, particularly the Rosetta Cancer Origin Test™, Rosetta's
development of personalized medicine products and services, Rosetta
licensing, partnering, entering into distribution agreements or
otherwise deriving value from microRNA technology for use in a
variety of diagnostic and targeted therapeutics and Rosetta
developing therapeutic products, the reproducibility, robustness
and accuracy of Rosetta's microRNA technology and its ability to
help optimize treatment and the extension of the agreement with
Genekor enhancing patient access to Rosetta testing services in
Romania and Turkey, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by these forward-looking statements as a
result of various important factors, including those risks more
fully discussed in the "Risk Factors" section of Rosetta's Annual
Report on Form 20-F for the year ended December 31, 2012 as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
Company Contact: Rosetta Genomics Ken Berlin President & CEO
(609) 419-9000, ext. 1326 investors@rosettagenomics.com Investor
Contacts: LHA Anne Marie Fields (212) 838-3777 afields@lhai.com or
Bruce Voss (310) 691-7100 bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024